Technical Analysis for ALGS - Aligos Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Flat |
| Historical ALGS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Multiple of Ten Bullish | Other | -0.61% | |
| Wide Bands | Range Expansion | -0.61% | |
| Multiple of Ten Bullish | Other | 5.12% | |
| Wide Bands | Range Expansion | 5.12% | |
| 20 DMA Resistance | Bearish | 3.64% | |
| Wide Bands | Range Expansion | 3.64% | |
| 20 DMA Resistance | Bearish | -5.83% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -5.83% | |
| Narrow Range Bar | Range Contraction | -5.83% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 4 hours ago |
| Up 2% | about 4 hours ago |
| 10 DMA Support | about 6 hours ago |
| Down 3% | about 7 hours ago |
| Down 2 % | about 8 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Alcohol Drug Development Coronavirus Hepatitis B Viruses Steatohepatitis Hepatitis Liver Disease Non Alcoholic Fatty Liver Disease Infectious Causes Of Cancer Liver Diseases Healthcare Associated Infections Viral Diseases Viral Infection Viral Infections Chronic Hepatitis Antiviral Therapies Chronic Hepatitis B
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Alcohol Drug Development Coronavirus Hepatitis B Viruses Steatohepatitis Hepatitis Liver Disease Non Alcoholic Fatty Liver Disease Infectious Causes Of Cancer Liver Diseases Healthcare Associated Infections Viral Diseases Viral Infection Viral Infections Chronic Hepatitis Antiviral Therapies Chronic Hepatitis B
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 37.465 |
| 52 Week Low | 12.82 |
| Average Volume | 64,497 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 24.36 |
| 20-Day Moving Average | 22.11 |
| 10-Day Moving Average | 21.38 |
| Average True Range | 2.30 |
| ADX | 13.69 |
| +DI | 14.74 |
| -DI | 21.65 |
| Chandelier Exit (Long, 3 ATRs ) | 19.64 |
| Chandelier Exit (Short, 3 ATRs ) | 24.70 |
| Upper Bollinger Band | 26.34 |
| Lower Bollinger Band | 17.87 |
| Percent B (%b) | 0.41 |
| BandWidth | 38.34 |
| MACD Line | -1.01 |
| MACD Signal Line | -1.15 |
| MACD Histogram | 0.1431 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 23.49 | ||||
| Resistance 3 (R3) | 23.50 | 22.80 | 23.13 | ||
| Resistance 2 (R2) | 22.80 | 22.25 | 22.79 | 23.01 | |
| Resistance 1 (R1) | 22.07 | 21.92 | 21.72 | 22.06 | 22.89 |
| Pivot Point | 21.37 | 21.37 | 21.20 | 21.36 | 21.37 |
| Support 1 (S1) | 20.64 | 20.82 | 20.29 | 20.63 | 19.79 |
| Support 2 (S2) | 19.94 | 20.49 | 19.93 | 19.67 | |
| Support 3 (S3) | 19.21 | 19.94 | 19.55 | ||
| Support 4 (S4) | 19.20 |
